Prevention and treatment of venous thromboembolism with low-molecular-weight heparins: Clinical implications of the recent European guidelines
2008
Preventing and Treating Venous Thromboembolism with Low-Molecular-Weight Heparins
publication
Evidence: moderate
Author Information
Author(s): Paolo Prandoni
Primary Institution: University of Padua, Italy
Hypothesis
Routine prophylaxis for at-risk patients is underused despite its importance in preventing VTE.
Conclusion
The study emphasizes the need for improved compliance with thromboprophylaxis guidelines to reduce morbidity and mortality from VTE.
Supporting Evidence
- VTE is a major cause of preventable illness and death.
- Routine thromboprophylaxis is underused despite its benefits.
- Patients with cancer have a significantly higher risk of VTE.
Takeaway
Doctors should give medicine to patients at risk of blood clots to help keep them safe, but many don't do it enough.
Methodology
This is a review of existing guidelines and evidence regarding the use of low-molecular-weight heparins for VTE.
Limitations
The review does not provide new clinical trial data but relies on existing guidelines and studies.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website